Effect of a Combination of Pemafibrate and a Mild Low-carbohydrate Diet on Obese and Non-obese Patients with MAFLD.
Yuichiro SuzukiShinya MaekawaKohji YamashitaLeona OsawaYasuyuki KomiyamaNatsuko NakakukiHitomi TakadaMasaru MuraokaMitsuaki SatoShinichi TakanoMitsuharu FukasawaTatsuya YamaguchiSatoshi FunayamaHiroyuki MorisakaHiroshi OnishiNobuyuki EnomotoPublished in: Journal of gastroenterology and hepatology (2023)
Combined treatment with pemafibrate and an LCD resulted in weight loss and improvements in ALT, MRE, and MRI-PDFF in MAFLD patients. Although such improvements were associated with weight loss in obese patients, the improvements were observed irrespective of weight loss in non-obese patients, indicating this combination can be effective both in obese and non-obese MAFLD patients.
Keyphrases
- weight loss
- obese patients
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- end stage renal disease
- metabolic syndrome
- newly diagnosed
- chronic kidney disease
- type diabetes
- magnetic resonance imaging
- prognostic factors
- glycemic control
- peritoneal dialysis
- weight gain
- physical activity
- magnetic resonance
- body mass index
- skeletal muscle
- smoking cessation